Hvsen Biotech released its performance for the first half of the year, turning a loss into a profit of 117 million yuan

Zhitong
2025.08.05 10:45
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Hvsen Biotech released its semi-annual report for 2025, showing an operating income of 822 million yuan, a year-on-year increase of 88.45%. The net profit attributable to shareholders of the listed company was 117 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.301 million yuan. The basic earnings per share were 0.6622 yuan. In addition, it plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders

According to the Zhitong Finance APP, Hvsen Biotech (300871.SZ) released its semi-annual report for 2025, showing an operating income of 822 million yuan, a year-on-year increase of 88.45%. The net profit attributable to shareholders of the listed company was 117 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.301 million yuan. The basic earnings per share were 0.6622 yuan. In addition, it plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.